Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269

The Meningococcal Antigen Typing System (MATS) has been developed as an hSBA surrogate to evaluate potential coverage afforded by the 4-component meningococcal serogroup B vaccine (4CMenB: Bexsero, GSK). We investigated whether the lower value of MATS coverage among invasive Meningococcus serogroup...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Hum Vaccin Immunother
Päätekijät: Stella, Maria, Giuliani, Maria, Biolchi, Alessia, Tomei, Sara, De Paola, Rosita, Bai, Xilian, Borrow, Ray, Lucidarme, Jay, La Gaetana, Rita, Toneatto, Daniela, Pizza, Mariagrazia, Serino, Laura, Mori, Elena, Giuliani, Marzia Monica
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2019
Aiheet:
Short Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7227617/
https://ncbi.nlm.nih.gov/pubmed/31770063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2019.1688039
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia